- Home
- AHG vs INBX Comparison
AHG vs INBX Comparison
Compare AHG & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- INBX
- Stock Information
- Founded
- AHG 2013
- INBX 2010
- Country
- AHG China
- INBX United States
- Employees
- AHG N/A
- INBX N/A
- Industry
- AHG Business Services
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- AHG Consumer Discretionary
- INBX Health Care
- Exchange
- AHG Nasdaq
- INBX Nasdaq
- Market Cap
- AHG 765.9M
- INBX 178.5M
- IPO Year
- AHG N/A
- INBX 2020
- Fundamental
- Price
- AHG $1.66
- INBX $22.86
- Analyst Decision
- AHG
- INBX Hold
- Analyst Count
- AHG 0
- INBX 1
- Target Price
- AHG N/A
- INBX N/A
- AVG Volume (30 Days)
- AHG 64.8K
- INBX 127.6K
- Earning Date
- AHG 07-29-2025
- INBX 08-12-2025
- Dividend Yield
- AHG N/A
- INBX N/A
- EPS Growth
- AHG N/A
- INBX N/A
- EPS
- AHG N/A
- INBX 111.58
- Revenue
- AHG $8,454,946.00
- INBX $200,000.00
- Revenue This Year
- AHG N/A
- INBX N/A
- Revenue Next Year
- AHG N/A
- INBX N/A
- P/E Ratio
- AHG N/A
- INBX $0.21
- Revenue Growth
- AHG 281.19
- INBX N/A
- 52 Week Low
- AHG $0.74
- INBX $10.80
- 52 Week High
- AHG $2.35
- INBX $24.30
- Technical
- Relative Strength Index (RSI)
- AHG 62.04
- INBX 85.32
- Support Level
- AHG $1.07
- INBX $20.48
- Resistance Level
- AHG $1.87
- INBX $15.25
- Average True Range (ATR)
- AHG 0.19
- INBX 1.33
- MACD
- AHG 0.06
- INBX 0.72
- Stochastic Oscillator
- AHG 60.20
- INBX 85.52
About AHG Akso Health Group ADS
Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.